“Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s72. doi:10.25251/skin.4.supp.72.